MedPath

Non-Invasive MOnitoring in Transcathether Aortic Valve Implantation

Not Applicable
Completed
Conditions
Aortic Valve Disease
Registration Number
NCT05840757
Lead Sponsor
University of Basel
Brief Summary

In patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) minimal evidence is available for invasive hemodynamic monitoring and no evidence for tools able to measure traditionally invasive parameters non-invasively for peri-procedural guidance and post-interventional management.

The aim of this study is to evaluate the effectiveness and safety of a non-invasive hemodynamics monitoring tool called ClearSight for monitoring during TAVI procedures compared with standard invasive measurements.

Detailed Description

In patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) minimal evidence is available for invasive hemodynamic monitoring and no evidence for tools able to measure traditionally invasive parameters non-invasively for peri-procedural guidance and post-interventional management.

The aim of this study is to evaluate the effectiveness and safety of a non-invasive hemodynamics monitoring tool called ClearSight for monitoring during TAVI procedures compared with standard invasive measurements.

The ClearSight monitoring system works non-invasively by utilizing an inflatable finger cuff which adjusts automatically to measure the arterial blood pressure which enables the calculation of parameters such as cardiac output or index. Multiple studies have demonstrated the reliability and feasibility of continuous non-invasive monitoring, in different settings, however it was never performed in patients undergoing TAVI.

The ClearSight monitoring system will be directly compared to invasive measurements of hemodynamic parameters during the procedure. In addition, information regarding baseline hemodynamics and its changes during/after procedure may give important information on peri- and post-procedural management and short-term outcomes and discharge planning. A tool, providing this information non-invasively with the same accuracy might result in a major improvement in daily practice..

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

• Adult patients (>18 years old) with severe aortic stenosis undergoing elective TAVI.

Exclusion Criteria
  • Emergency indication for TAVI
  • Severe tricuspid regurgitation
  • Severe mitral stenosis or severe regurgitation
  • Invasive right heart catheterization impossible
  • Dependency on right ventricle pacing immediately after TAVI implantation
  • Vulnerable subjects
  • Known or suspected non-compliance, drug or alcohol abuse
  • Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation affecting this study
  • Previous enrolment into the current investigation

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Cardiac OutputDuring aortic valve implantation which generally takes about 40mins

Cardiac Output (CO in L/min)

Diastolic blood pressureDuring aortic valve implantation which generally takes about 40mins

diastolic blood pressure (dBP in mmHg)

Cardiac IndexDuring aortic valve implantation which generally takes about 40mins

Cardiac Index (CI in L/min/m2)

Systolic blood pressureDuring aortic valve implantation which generally takes about 40mins

systolic blood pressure (sBP in mmHg)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Hospital Basel

🇨🇭

Basel, BS, Switzerland

University Hospital Basel
🇨🇭Basel, BS, Switzerland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.